Alembic Pharmaceuticals vs Nifty 50: Returns Compared
- August 31, 2026
- Posted by: Kunal Singla
- Category: Market
Alembic Pharmaceuticals share price Rs 813.70 on NSE. Alembic Pharmaceuticals vs Nifty 50 over 1 year: -13.68% vs -2.41%. 52-week high Rs 998.00, low Rs 635.80.
Quick Answer
Alembic Pharmaceuticals vs Nifty 50 shows Alembic Pharmaceuticals trailing the benchmark on a one-year view, with a return of -13.68% against the Nifty 50’s -2.41%. Over the longer term the index has pulled ahead, a reminder that short-term outperformance does not always hold up over multi-year horizons. Investors comparing the two should also weigh Alembic Pharmaceuticals’s trading liquidity, valuation and sector context rather than relying on returns alone.
Alembic Pharmaceuticals vs Nifty 50 is a comparison that looks different depending on the time frame chosen. Alembic Pharmaceuticals trades on the NSE under the symbol APLLTD, and its 1M return of +2.09% compares with the Nifty 50’s -1.44% over the same period.
The Alembic Pharmaceuticals vs Nifty 50 comparison matters because Alembic Pharmaceuticals is a single stock exposed to its own sector and company-specific developments, while the Nifty 50 spreads risk across 50 large companies. This article lines up Alembic Pharmaceuticals share price performance against the Nifty 50 across 1 month, 3 months, 6 months, 1 year, 3 years, 5 years, using NSE closing data.
Click Here – Get Free Investment Predictions
Alembic Pharmaceuticals vs Nifty 50: Performance at a Glance
The table below sets out Alembic Pharmaceuticals vs Nifty 50 performance across the available time frames, measured from NSE closing prices up to 31 August 2026.
| Time Frame | Alembic Pharmaceuticals Return | Nifty 50 Return | Difference |
|---|---|---|---|
| 1 Month | +2.09% | -1.44% | +3.53% pp |
| 3 Months | +13.01% | +2.78% | +10.24% pp |
| 6 Months | +15.38% | -3.35% | +18.73% pp |
| 1 Year | -13.68% | -2.41% | -11.27% pp |
| 3 Years | +5.61% | +23.65% | -18.04% pp |
| 5 Years | +7.75% (Alembic Pharmaceuticals) | +40.73% (Nifty 50) | -32.98% pp |
On the Alembic Pharmaceuticals vs Nifty 50 scorecard, Alembic Pharmaceuticals has lagged the index over the most recent one-year window. Over the longer term the index has pulled ahead, a reminder that short-term outperformance does not always hold up over multi-year horizons.
Check the Univest Screener for live Alembic Pharmaceuticals and Nifty 50 data
Why the Alembic Pharmaceuticals vs Nifty 50 Gap Exists
Alembic Pharmaceuticals’s stock can move quite differently from the Nifty 50 because it carries concentrated exposure to its own sector and business cycle, unlike the index which blends 50 companies across banking, IT, energy and consumer sectors. This is the main driver of the gap seen in the Alembic Pharmaceuticals vs Nifty 50 return table above.
A second factor behind the Alembic Pharmaceuticals vs Nifty 50 divergence is valuation and trading liquidity. Company-specific news, quarterly results and sector sentiment can move Alembic Pharmaceuticals’s price sharply in either direction over short periods, while the Nifty 50’s return reflects the blended earnings trajectory of its constituents and is far less exposed to any single stock’s swings.
Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals and Nifty 50 live on the go.
Alembic Pharmaceuticals vs Nifty 50: Has Alembic Pharmaceuticals Beaten the Benchmark?
Alembic Pharmaceuticals has not kept pace with the Nifty 50 over the past year, posting a return of -13.68% against the index’s -2.41% over the same period. The longer-term picture is similarly weaker than the benchmark.
Risks of the Alembic Pharmaceuticals vs Nifty 50 Comparison
Reading too much into a Alembic Pharmaceuticals vs Nifty 50 comparison has real limitations that investors should weigh before drawing conclusions. Alembic Pharmaceuticals carries concentrated business and sector risk that a diversified index does not, and its trading volumes and price swings can differ meaningfully from the Nifty 50’s more liquid, blended profile. A stock’s 52-week range of Rs 635.80 to Rs 998.00 also shows the kind of volatility that a single-stock investment carries relative to a broad index.
Conclusion
Alembic Pharmaceuticals vs Nifty 50 highlights how a single stock’s return path can differ from a diversified benchmark over different time horizons. Investors comparing Alembic Pharmaceuticals against a Nifty 50 index fund should factor in the stock’s volatility, liquidity and sector concentration alongside its return history, and consult a SEBI-registered advisor before making an allocation decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Has Alembic Pharmaceuticals outperformed the Nifty 50 in the last year?
Ans. No. Alembic Pharmaceuticals returned -13.68% over the past year while the Nifty 50 returned -2.41% over the same period, based on NSE closing prices to 31 August 2026.
How does Alembic Pharmaceuticals vs Nifty 50 look over 5 years?
Ans. Over five years Alembic Pharmaceuticals has returned +7.75% compared with the Nifty 50’s +40.73%, so in the Alembic Pharmaceuticals vs Nifty 50 comparison the index has been ahead over this longer horizon.
What is the Alembic Pharmaceuticals share price today compared to Nifty 50?
Ans. Alembic Pharmaceuticals share price stood at Rs 813.70 on NSE, while the Nifty 50 traded at 24,031.60 based on the same closing data window.
What is the 52-week high and low of Alembic Pharmaceuticals?
Ans. Alembic Pharmaceuticals’s 52-week high is Rs 998.00 and its 52-week low is Rs 635.80, based on NSE data.
Why does Alembic Pharmaceuticals show bigger price swings than the Nifty 50?
Ans. Alembic Pharmaceuticals carries concentrated exposure to its own sector and business cycle, while the Nifty 50 spreads risk across 50 large companies, so company-specific news moves Alembic Pharmaceuticals’s price more sharply than the diversified index, a key reason the Alembic Pharmaceuticals vs Nifty 50 return gap varies across time frames.
Is Alembic Pharmaceuticals a good long-term investment compared to a Nifty 50 index fund?
Ans. Alembic Pharmaceuticals’s suitability depends on an investor’s risk appetite, since single-stock exposure carries higher concentration risk than a diversified Nifty 50 index fund; long-term investors should weigh the Alembic Pharmaceuticals vs Nifty 50 return history alongside the company’s fundamentals and consult a SEBI-registered advisor.
